# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Leber congenital amaurosis

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 27 results.
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.
Status: Completed
Last Changed: Nov 21, 2016
First Received: Nov 21, 2016
Disease(s): Leber Congenital Amaurosis
Locations: Necker-Enfants Malades Hospital, Paris, France
Study to Evaluate QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Status: Completed
Last Changed: Jan 18, 2020
First Received: May 04, 2017
Disease(s): Leber's Congenital Amaurosis
Intervention(s): QR-110
Locations: University of Iowa, Iowa City, Iowa, United States
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Ghent University Hospital and Ghent University, Ghent, Belgium
Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Status: Active, not recruiting
Last Changed: Feb 19, 2020
First Received: Apr 18, 2019
Disease(s): Leber's Congenital Amaurosis
Intervention(s): SAR439483, SAR439483 Diluent Solution, Prednisone, Triamcinalone Acetonide, 1% Prednisolone, Trimethoprim/polymyxin B
Locations: Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
Status: Recruiting
Last Changed: Jul 16, 2019
First Received: Mar 22, 2016
Disease(s): Leber Congenital Amaurosis
Locations: Kellogg Eye Center, Ann Arbor, Michigan, United States
Moorfields Eye Hospital, London, United Kingdom
Safety Study in Subjects With Leber Congenital Amaurosis
Status: Active, not recruiting
Last Changed: Jul 11, 2019
First Received: Aug 15, 2007
Disease(s): Leber Congenital Amaurosis
Intervention(s): voretigene neparvovec-rzyl
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Status: Completed
Last Changed: Dec 28, 2017
First Received: Sep 10, 2008
Disease(s): Leber Congenital Amaurosis
Intervention(s): rAAV2-CB-hRPE65
Locations: University of Massachusetts Medical School, Worcester, Massachusetts, United States
Casey Eye Institue, Oregon Health & Science University, Portland, Oregon, United States
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
Status: Active, not recruiting
Last Changed: Jul 11, 2019
First Received: Sep 24, 2010
Disease(s): Leber Congenital Amaurosis
Intervention(s): voretigene neparvovec-rzyl
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Status: Completed
Last Changed: Jul 17, 2019
First Received: May 24, 2016
Disease(s): Leber Congenital Amaurosis
Intervention(s): AAV RPE65
Locations: Kellogg Eye Centre, University of Michigan, Ann Arbor, Michigan, United States
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
Status: Active, not recruiting
Last Changed: May 18, 2020
First Received: Oct 22, 2009
Disease(s): Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Intervention(s): AAV2-hRPE65v2,voretigene neparvovec-rzyl
Locations: University of Iowa, Iowa City, Iowa, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Status: Completed
Last Changed: Apr 10, 2018
First Received: Jan 13, 2009
Disease(s): Leber Congenital Amaurosis
Intervention(s): rAAV2-hRPE65
Locations: Hadassah Medical Organization, Jerusalem, Israel